Best Growth Stocks to Buy for October 26th

Zacks highlighted Petco, Five Below, and Oscar Health as Rank #1 stocks with rising current-year earnings estimates. Consensus estimates increased over the past 60 days by 26.3% for Petco, 15.2% for Five Below, and 18.8% for Oscar Health. The article provides stock-selection commentary, not reported company results or share-price reactions.

Analysis

This is a screen, not a fresh fundamental catalyst: estimate revisions can reflect improving operating evidence, but the article gives no earnings base, revision drivers, valuation, or revision breadth. The signal is therefore more useful as a diligence queue than a reason to buy all three.

The businesses have distinct risks. For Five Below (FIVE), test whether revisions are supported by traffic and comparable sales rather than temporary cost actions; a value-retail positioning can still be vulnerable to a pressured discretionary consumer and competition from Dollar Tree, Dollar General, and Walmart. For Petco (WOOF), confirm that estimate changes translate into recurring comparable-sales and cash-flow improvement; otherwise earnings revisions may not resolve balance-sheet or execution concerns. For Oscar Health (OSCR), earnings quality depends on underwriting and medical-cost trends, while policy and marketplace changes can overwhelm near-term model improvements. These are different exposures, not a coherent basket.

Over days, the list may attract momentum-driven retail flows, but that is not evidence of durable alpha. Over 1–3 months, earnings releases and guidance should reveal whether estimates are being validated; over 6–18 months, consumer demand, operating execution, and healthcare policy are the key differentiators. The contrarian point: repeated estimate increases look compelling in percentage terms but say little without the starting estimate, actual earnings power, or valuation. No trade is warranted from this article alone.

Key Decisions for Investors

• Do not initiate a basket position solely on the Zacks rank or revision percentages; first verify revision breadth, the underlying earnings base, and whether changes reflect operating performance versus accounting or one-off assumptions.
• Put FIVE on a conditional watchlist: consider exposure only if upcoming results support estimates with traffic/comparable-sales evidence; reassess if guidance weakens or value-retail peers show broad demand deterioration.
• Keep WOOF as a diligence-only candidate until reported comparable sales, cash generation, and balance-sheet metrics demonstrate that higher estimates are translating into durable financial improvement. A failure to convert earnings into cash would falsify the bullish case.
• For OSCR, track medical-cost/underwriting indicators and policy developments before taking directional risk. A deterioration in cost trends or an adverse marketplace/regulatory change would outweigh this estimate-revision signal.